Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX – Get Free Report) saw a large increase in short interest in the month of September. As of September 15th, there was short interest totaling 45,625 shares, an increase of 58.3% from the August 31st total of 28,830 shares. Based on an average trading volume of 33,064 shares, the short-interest ratio is currently 1.4 days. Currently, 1.5% of the shares of the stock are short sold.
Wall Street Analysts Forecast Growth
A number of research analysts recently issued reports on ELOX shares. Guggenheim reissued a “buy” rating and issued a $43.00 price objective on shares of Eloxx Pharmaceuticals in a research note on Monday, August 24th. Lucid Cap Mkts raised Eloxx Pharmaceuticals to a “strong-buy” rating in a report on Thursday, August 20th. Wall Street Zen upgraded Eloxx Pharmaceuticals to a “hold” rating in a research note on Saturday, August 1st. Leerink Partners set a $32.00 price target on Eloxx Pharmaceuticals and gave the stock an “outperform” rating in a report on Friday, September 18th. Finally, Lifesci Capital started coverage on Eloxx Pharmaceuticals in a research report on Wednesday, July 22nd. They set an “outperform” rating and a $40.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $38.33.
View Our Latest Stock Analysis on ELOX
Eloxx Pharmaceuticals Stock Performance
Eloxx Pharmaceuticals (NASDAQ:ELOX – Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.66) EPS for the quarter.
Eloxx Pharmaceuticals Company Profile
Eloxx Pharmaceuticals, Inc was a clinical-stage biopharmaceutical company focused on developing therapies for genetic diseases caused by nonsense mutations, which can prevent cells from producing functional proteins. The company’s research platform centered on ribosome modulation, an approach intended to encourage cells to read through certain premature stop signals in genetic instructions.
Its lead product candidate, ELX-02, was an investigational small-molecule therapy designed to promote the production of full-length proteins in diseases associated with nonsense mutations.
Featured Stories
- Five stocks we like better than Eloxx Pharmaceuticals
- Saddle Up: Texas Stock Exchange Ropes In $80 Billion in Listings
- Why Concentra’s Quiet Healthcare Business Keeps Winning
- Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
- Alamos Gold’s 1 Million-Ounce Growth Story Is Hiding in Plain Sight
Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
